We are excited to announce that we have completed construction of a new 38,000 square feet biologics biosafety testing facility in Suzhou, China.  Operations will begin after validations are completed this summer.

The service offerings at this facility will include clinical and commercial lot release programs, viral clearance testing, and virus and molecular-based safety detection services for Chinese and multinational customers.  The new services will expand WuXi’s already broad, integrated platform of biologic services.  In the United States, WuXi offers biosafety testing services such as viral clearance validation and lot release and stability testing.  In China, our services include novel monoclonal antibody discovery, discovery biology, drug screening, cell-line engineering and construction, toxicology, bioanalytical services, assay development, formulation, process development, and cGMP drug-substance and drug-product manufacturing for clinical trials.

Our goal is to become a leading biologics solution provider that helps our customers advance their biologic product candidates through development more quickly and cost-effectively.


Related links:

See official press release here.
Immutep and Eddingpharm start production of ImmufactIMP321 at WuXi
FDA Approves Ibalizumab Manufactured by WuXi for Treatment of Patients on Expanded Access